Skip to main content
. Author manuscript; available in PMC: 2016 Oct 10.
Published in final edited form as: Eur Urol. 2015 May 16;68(4):570–577. doi: 10.1016/j.eururo.2015.04.032

Table 2.

Clinical outcomes for treatment with and without concomitant bone-targeted therapy (BTT)

BTT No BTT HR (95% CI)a p value
Median rPFS (mo) 13.6 11.0 0.86 (0.72–1.02) 0.08
Median overall survival (mo) NE 30.3 0.75 (0.60–0.94) 0.012
Median time to opiate use for CaRP (mo) NE 27.9 0.80 (0.65–0.99) 0.036
Median time to chemotherapy initiation (mo) 22.4 21.1 0.92 (0.76–1.10) 0.4
Median time to ECOG PS deterioration (mo) 14.3 11.1 0.75 (0.64–0.87) <0.001
Median time to PSA progression (mo) 8.3 8.3 0.88 (0.75–1.03) 0.11

CaRP = cancer-related pain; CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; HR = hazard ratio; NE = not estimable; PSA = prostate-specific antigen; rPFS = radiographic progression-free survival.

a

Stratified Cox model with concomitant BTT use, treatment, and key baseline parameters (PSA, lactate dehydrogenase, alkaline phosphatase, hemoglobin, and whether a patient had bone metastases only at entry) as factors. When the interaction effect of treatment and BTT use was included in the models, the p values were not significant (rPFS, p = 0.18; OS, p = 0.13; time to opiate use for Ca-RP, p = 1.0; time to chemotherapy initiation, p = 0.9; time to ECOG PS deterioration, p = 0.18; time to PSA progression, p = 0.8).